INTRODUCTION AND OBJECTIVES: Adjuvant radiotherapy (aRT) in patients with adverse pathology following radical prostatectomy (RP) improves biochemical progression-free survival. Nevertheless, a wait-and-see policy followed by salvage radiotherapy (sRT) if biochemical recurrence (BCR) occurs is often preferred, reducing overtreatment. Prospective randomized controlled trials to determine if aRT is superior to sRT are ongoing, but due to the longterm oncologic outcome will take several years to become available.
To determine predictors for BCR (defined by two consecutive rising PSA values >0.2 ng/ml) following RP in patients with adverse pathology, supporting decision making which patients to select for aRT.
METHODS: We retrospectively analysed all patients with adverse pathology following RP (defined by pT2R1 or pT3), with no lymph node involvement, undetectable postoperative PSA values (<0.1 ng/ml) and no adjuvant treatment from the ERSPC Rotterdam database. A Cox proportional hazard model was used to assess the association between prognostic factors comprising of grade group (GG), pathological stage, surgical margin, preoperative PSA (log2(-PSA)), and BCR. Follow-up was defined as the time between RP and BCR, death, or censoring (2016-12-31) .
RESULTS: Our cohort consisted of 355 patients who underwent RP between 1991 and 2016. Median follow up was 12.2 (IQR 7.9 e 16.9) years. A total of 128 men experienced BCR. GG, pathological stage, log2(PSA) and surgical margin were independent predictors for BCR, see Figure 1 . Patients in GG 4-5 are most at risk of experiencing BCR (hazard ratio (HR): 5.57 95%CI: 3.00-10.3 p<0.001 in comparison to GG1). Low-risk patients, defined as GG 1 and pT3a, have a risk of 11% (95% CI 6%-16%) of experiencing BCR at 10 years following RP. For all other patients, this risk is 38% (95%CI 30%-44%).
CONCLUSIONS: GG, pathological stage, log2(PSA) and surgical margins can be used to select patients who probably benefit most for aRT. Especially patients with GG 4-5 and/or pT3b are at risk for BCR and therefore might benefit most from aRT. In the low-risk group (39% of our cohort) aRT would be considered overtreatment in almost 9 out of 10 patients. Overtreatment, being the major problem of aRT, can be reduced drastically by avoiding its use in low-risk patients.
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MP72-11 PERSISTENT UNDER-UTILIZATION OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH ADVERSE PATHOLOGICAL FEATURES AT RADICAL PROSTATECTOMY (RP): A NATIONAL CANCER DATABASE (NCDB) ANALYSIS
Nikola Rakic*, Audrey Fotouhi, Lee Baumgarten, Alex Borchert, Deepansh Delela, Akshay Sood, Sohrab Arora, Jacob Keeley, Mani Menon, Firas Abdollah, Detroit, MI INTRODUCTION AND OBJECTIVES: Three trials showed the benefit of adjuvant radiotherapy (aRT) in patients with adverse pathological features at the time of RP. Additionally, recent data showed that patients with very aggressive features benefit the most from aRT. We set to examine the utilization and impact on overall survival (OS) of aRT over the last decade in patients with adverse pathological features.
METHODS: We identified 189,240 prostate cancer patients with adverse features at RP (positive margin, pT3a or higher, and/or pN1 disease), who were treated between 2004 and 2015, within the NCDB. We first examined the utilization of aRT in these patients , and tested for changes over time. We then propensity-score matched patients who received aRT to their counterparts, who received no aRT and evaluated the impact of aRT on OS using cox regression analysis. Finally, we focused on patients with very aggressive features (at least two of: pT3b or higher, pathological Gleason 8-10, and pN1), and repeated the aforementioned analyses.
RESULTS: In patients with adverse features, only 11.7% (22,320) 29.6% in 2015 (p[.4 ). In patients with any adverse pathology, the 120-month OS was 72.0% in aRT patients vs. 72.4% in patients without aRT (p[.3). In patients with very aggressive features, this rate was 56.6% in aRT patients vs. 53.7% in patients without aRT (p[.008). In patients with adverse pathological features, aRT was not an independent predictor of OS (HR: 1.01 95% CI 0.94-1.08 p-value: .6). Conversely, in individuals with very aggressive pathological features, aRT patients had more favorable OS compared to their nonaRT counterparts (HR: 0.88 95% CI, 0.80-0.98, p-value: .01). CONCLUSIONS: On a national level, there is a severe underutilization of aRT, which did not improve over time. This is true even in patients with very aggressive pathological features. This indicates a sub-optimal quality of care, especially given the evident survival benefit of aRT in these patients. While an aRT survival benefit was not evident in our cohort of patients with any adverse pathological features, this might be due to the severe selection bias against aRT in clinical practice. Our findings highlight a quality-of-care concern, and indicate that urgent efforts are needed to improve the current practice pattern in the United States.
Source of Funding: None
MP72-12 COMPARISON OF LONG-TERM OUTCOMES BETWEEN RADICAL PROSTATECTOMY AND INTENSITY-MODULATED RADIATION THERAPY FOR HIGH-RISK LOCALIZED PROSTATE CANCER: A SINGLE-CENTER PROPENSITY SCORE-MATCHED ANALYSIS
Ryuji Matsumoto*, Satoru Maruyama, Jun Furumido, Haruka Miyata, Hiroshi Kikuchi, Takahiro Osawa, Takashige Abe, Nobuo Shinohara, Sapporo, Japan INTRODUCTION AND OBJECTIVES: The guidelines of the National Comprehensive Cancer Network recommend radiation therapy plus androgen deprivation therapy (ADT) with category 1 evidence for high-risk localized prostate cancer (HR-LPCa) in patients with a life expectancy of at least 5 years. Radical prostatectomy (RP) plus pelvic lymph node dissection can be considered as an acceptable initial therapy in young and healthy patients. However, to our knowledge, no randomized study at a single center has assessed the Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1059
Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
